Research programme: toll-like receptor 7 modulators - Cancer Research Technology/Innate PharmaAlternative Names: IPH 3201
Latest Information Update: 18 Jun 2010
At a glance
- Originator Cancer Research Technology
- Developer Cancer Research Technology; Innate Pharma
- Mechanism of Action Toll-like receptor 7 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Feb 2009 This programme is still in active development